导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.25% | 2767/4765 |
| 近一周 | -1.79% | 2820/5455 |
| 近一月 | -3.55% | 2620/5411 |
| 近一季 | -6.82% | 2557/5221 |
| 近半年 | -2.31% | 2080/4910 |
| 近一年 | 1.23% | 2528/4390 |
| 近两年 | 42.90% | 1778/2953 |
| 近三年 | 25.46% | 1289/2252 |
| 成立以来 | 50.74% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.38% 3172/4961 |
11.86% 2281/5312 |
- - |
- - |
| 2025 | 18.86% 2275/4813 |
-1.00% 2522/3635 |
1.90% 2034/4076 |
17.78% 2439/4524 |
0.04% 2273/4813 |
| 2024 | 14.93% 985/3463 |
2.67% 730/2808 |
-1.10% 928/3014 |
15.21% 1786/3129 |
-1.77% 1822/3463 |
| 2023 | -9.46% 1166/2656 |
3.85% 1107/2280 |
-3.94% 979/2385 |
-2.90% 784/2515 |
-6.53% 1816/2655 |
| 2022 | -19.39% 842/2207 |
-13.89% 862/1919 |
6.22% 747/2016 |
-13.30% 876/2113 |
1.65% 1193/2208 |
| 2021 | -3.77% 928/1822 |
-3.09% 756/1255 |
4.23% 909/1330 |
-5.61% 833/1466 |
0.93% 1040/1822 |
| 2020 | 27.50% 578/1250 |
-10.10% 754/1028 |
13.15% 645/1067 |
10.76% 515/1164 |
13.16% 384/1184 |
| 2019 | 35.50% 375/1092 |
26.27% 415/754 |
-0.22% 238/804 |
0.73% 476/850 |
6.77% 552/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.92% 384/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华泰柏瑞沪深300ETF联接C VS. 长安沪深300非周期A(740101) |